September 19, 2021
  • September 19, 2021
  • Home
  • International Productivity
  • NGM Bio to Host Conference Call to Discuss Key Findings from the 24-Week ALPINE 2/3 Phase 2b Study of Aldafermin in NASH

NGM Bio to Host Conference Call to Discuss Key Findings from the 24-Week ALPINE 2/3 Phase 2b Study of Aldafermin in NASH

By on May 23, 2021 0



News and research before you hear about it on CNBC and others. Claim your 1-week free trial for StreetInsider Premium here.


SOUTH SAN FRANCISCO, Calif., May 23, 2021 (GLOBE NEWSWIRE) – NGM Biopharmaceuticals, Inc. (Nasdaq: NGM) will host a conference call and live webcast on Monday, May 24, 2021 at 8:30 a.m. ET (5:30 a.m. PT) to discuss the first results of the 24-week ALPINE 2/3 phase 2b study evaluating doses of 0.3 mg, 1 mg and 3 mg of aldafermine compared to placebo in patients with non-alcoholic steatohepatitis, or NASH , stage 2 or 3 hepatic fibrosis. The details of the conference call and webcast are as follows:

Live conference call
National callers: (844) 873-0551
International callers: (602) 563-8472
Access code: 9393531

Live and archived Webcast
For live or archived webcast, please visit the “Investors and Media” section of the NGM website at https://ir.ngmbio.com/. The webcast will be archived for 30 days.

Archived conference call
National callers: (855) 859-2056
International callers: (404) 537-3406
Access code: 9393531

The archived conference call will be available for 30 days.

About NGM Biopharmaceuticals, Inc.

NGM is a biopharmaceutical company focused on the discovery and development of new therapies based on scientific understanding of the major biological pathways underlying liver and metabolic disease, retinal disease and cancer. We are leveraging our biologically-centric drug discovery approach to discover novel mechanisms of action and generate proprietary information that allows us to move quickly to proof-of-concept studies and provide patients with potential first-rate drugs. order. At NGM, we aspire to operate one of the most productive research and development engines in the biopharmaceutical industry. Visit us at www.ngmbio.com for more information.



Source link